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CLINICAL HISTORY

Figure 1. MRI showing left
supraclavicular mass.

The patient is a 66-year-old female who
presented with a left supraclavicular
mass (5.7 cm on ultrasound). An
MRI scan (Fig.1) was performed and
confirmed a mass displacing the left
sternocleidomastoid muscle anteriorly
with mixed cystic and solid appearance.
CT scan of the chest and abdomen did
not show additional lymphadenopathy.
The patient reported history of chronic
fatigue, and a remote history of right
nephrectomy. A CBC was unremarkable
except for a chronic normocytic anemia
with hemoglobin of 10.4 g/dL.
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HISTOLOGIC FINDINGS
Histologic sections revealed a well-circumscribed, mostly encapsulated
tumor composed of spindle to ovoid cells, which in areas formed
whorls, particularly around small vessels (Fig. 2A, 2B). The tumor cells
showed indistinct cell borders and nuclei with vesicular to granular
chromatin, variably prominent nucleoli, occasional multinucleation, and
scattered pseudo-nuclear inclusions. There was significant cytologic
atypia/pleomorphism (Fig. 2C). Areas of necrosis were noted (Fig.
2D). Perivascular lymphocyte aggregation was also seen. The mitotic
count ranged from 4 to 9 mitoses per 10 high power fields.
An extensive panel of immunostains was performed (Fig. 3) and
revealed that the tumor cells were strongly and diffusely positive
for vimentin, CD21, CD35, CD23, and showed patchy membranous
staining with D240. The tumor cells were negative immunostains for
CD1a, AE1/3, EMA, CD45, CD20, CD3, CD4, CD8, CD34, CD56, CD68,
chromogranin, synaptophysin, p63, PAX8, TTF1, Mart1, S100, and
HMB45.

Follicular dendritic cell sarcoma (FDCS) is a neoplastic proliferation of spindled to
ovoid follicular dendritic cells. This neoplasm is rare with wide age spectrum. The
median age of patients according to one study was 48 years, and they had an equal
sex distribution. Cervical lymph nodes are the most common site. However disease
can present extranodally. Patients usually present with slowly growing painless
mass. Systemic symptoms are uncommon. The morphology is that of spindle to
ovoid cells forming fascicles, storiform arrays / whorls around blood vessels, diffuse
sheets and vague nodularity. The mitotic rate is usually between 0 and 10/ 10 highpower fields (HPF). The more pleomorphic cases demonstrate a higher mitotic
rates (>30/ 10 HPF). Nuclear atypia is highly variable. Necrosis and hemorrhage
can be seen. The Immunophenotype is always positive for one or more of the FDC
markers such as CD21, CD45, CD23 and CD35. The tumor is variably positive for
CD68, S100 and negative for CD1a. The behavior is usually indolent. High-grade
features such as overt cytologic atypia, extensive coagulative necrosis and a high
proliferative index, and large tumour size or intraabdominal location are associated
with an adverse prognosis. No prospective studies of treatments and outcomes
in patients with FDCS have been reported which make it difficult to provide firm
treatment recommendations. However, most patients are treated by complete
surgical excision, with or without adjuvant radiotherapy or chemo -therapy. Local
recurrences occur in more than 50% of cases, and metastases occur in about 25%
of patients. Our case presented with unifocal disease and therefore was treated with
excision and radiation therapy. No further clinical follow up on this patient as of this
time to evaluate further response.
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